[8] In line 274, please change "OR 1.51" to "OR 1.51 [... - ...]", i.e.
It would be nice to know the selumetinib sensitivity of the two used cell lines. The concentration used from selumetinib both for the cell line experiments (10 microM) and for the animal experiments (50mg/kg) are quite high. Please discuss how the applied concentrations are related to the clinicaly used dosage (75 mg administered orally twice https://clinicaltrials.gov/ct2/show/NCT02448290) and why not the more efficient MEK1 inhibitor trametinib was used for the experiments.